News

Mena FN8d
Immix Biopharma Announces Primary Endpoint Met In Positive NXC-201 Interim Results Presented At ASCO, Enabling Path To Best-In-Class Therapy For Relapsed/Refractory AL Amyloidosis
(MENAFN- GlobeNewsWire - Nasdaq) Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint.
Bleeping Computer28d
Focused Phishing: Attack Targets Victims With Trusted Sites and Live Validation
The email validation technique is executed through either client-side code or API calls. In this case, the email validation appears to happen server-side, not client-side via JavaScript.
GitHub5d
[API Proposal]: Expose _mm512_cmp_ps_mask intrinsic in Avx512F class
api-suggestionEarly API idea and discussion, it is NOT ready for implementationEarly API idea and discussion, it is NOT ready for implementationarea-System.Runtime ...
GitHub14d
JOPA - Java OWL Persistence API
The library architecture and API is similar to JPA (see [2]) so that Java developers find it familiar ... There are limitations to this: JOPA requires explicit class assertion to be able to load ...